Autologous chondrocyte implantation - TiGenix

Drug Profile

Autologous chondrocyte implantation - TiGenix

Alternative Names: ChondroCelect; ChondroCelect-3D; TGX 001; TGX 002; TGX002/FAB002

Latest Information Update: 15 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator TiGenix
  • Class Cell therapies
  • Mechanism of Action Cartilage replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Cartilage disorders

Highest Development Phases

  • Suspended Cartilage disorders

Most Recent Events

  • 05 Jul 2016 Discontinued - Registered for Cartilage disorders in Liechtenstein, Norway, Iceland, European Union (Parenteral)
  • 05 Jul 2016 Withdrawn for Cartilage disorders in Spain, Finland, Luxembourg, Ireland, Czech Republic, Poland, Portugal, Austria, France, United Kingdom, Belgium, Netherlands, Germany (Parenteral)
  • 30 Jun 2014 Committee for Medicinal Products for Human Use renews marketing authorisation for autologous chondrocyte implantation in European Union, Iceland, Norway and Liechtenstein (9167388; 9165318)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top